Drug Approval | August 25, 2024
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
